INR 45.73
(-0.24%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 12.99 Million INR | -35.43% |
2022 | 12.64 Million INR | -14.63% |
2021 | 14.83 Million INR | -38.2% |
2020 | 23.74 Million INR | 18.66% |
2019 | 19.73 Million INR | 79.76% |
2018 | 11.02 Million INR | 8.56% |
2017 | 10.04 Million INR | -62.53% |
2016 | 27.58 Million INR | 97.22% |
2015 | 13.97 Million INR | 15.79% |
2014 | 11.95 Million INR | 16.64% |
2013 | 10.2 Million INR | -4.71% |
2012 | 10.71 Million INR | 141.28% |
2011 | 4.5 Million INR | -61.46% |
2010 | 11.7 Million INR | 78.55% |
2009 | 6.55 Million INR | 566.81% |
2008 | -2.74 Million INR | 48.72% |
2007 | -2.73 Million INR | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q1 | 3.08 Million INR | -9.57% |
2023 Q4 | -326 Thousand INR | -114.77% |
2023 FY | - INR | -35.43% |
2023 Q2 | 2.69 Million INR | -38.99% |
2023 Q3 | 2.2 Million INR | -18.23% |
2023 Q1 | 4.42 Million INR | 0.23% |
2022 Q1 | 3.93 Million INR | 131.18% |
2022 FY | - INR | -14.63% |
2022 Q4 | 4.41 Million INR | 75.72% |
2022 Q3 | 2.51 Million INR | 40.89% |
2022 Q2 | 1.78 Million INR | -54.71% |
2021 Q1 | 3.53 Million INR | -1.86% |
2021 Q3 | 5.54 Million INR | 37.48% |
2021 FY | - INR | -38.2% |
2021 Q4 | 1.7 Million INR | -69.28% |
2021 Q2 | 4.03 Million INR | 14.03% |
2020 Q3 | 6.32 Million INR | -40.07% |
2020 FY | - INR | 18.66% |
2020 Q1 | 3.43 Million INR | -38.34% |
2020 Q2 | 10.55 Million INR | 207.66% |
2020 Q4 | 3.6 Million INR | -43.06% |
2019 Q3 | 3.52 Million INR | -61.61% |
2019 FY | - INR | 79.76% |
2019 Q1 | 2.33 Million INR | -27.94% |
2019 Q2 | 9.18 Million INR | 292.69% |
2019 Q4 | 5.56 Million INR | 57.86% |
2018 Q2 | 2.15 Million INR | 21.11% |
2018 FY | - INR | 8.56% |
2018 Q3 | 4.06 Million INR | 88.89% |
2018 Q1 | 1.77 Million INR | -43.57% |
2018 Q4 | 3.24 Million INR | -20.11% |
2017 Q1 | 2.06 Million INR | -87.57% |
2017 FY | - INR | -62.53% |
2017 Q4 | 3.14 Million INR | -5.29% |
2017 Q3 | 3.32 Million INR | 82.78% |
2017 Q2 | 1.81 Million INR | -11.83% |
2016 FY | - INR | 97.22% |
2016 Q1 | 1.28 Million INR | -84.47% |
2016 Q2 | 3.76 Million INR | 194.07% |
2016 Q3 | 5.94 Million INR | 57.87% |
2016 Q4 | 16.58 Million INR | 178.93% |
2015 Q2 | 1.93 Million INR | 22.61% |
2015 Q4 | 8.24 Million INR | 272.28% |
2015 Q3 | 2.21 Million INR | 14.41% |
2015 Q1 | 1.57 Million INR | -70.99% |
2015 FY | - INR | 15.79% |
2014 FY | - INR | 16.64% |
2014 Q4 | 5.44 Million INR | 106.73% |
2014 Q3 | 2.63 Million INR | 8.35% |
2014 Q2 | 2.43 Million INR | 69.22% |
2014 Q1 | 1.43 Million INR | -46.35% |
2013 FY | - INR | -4.71% |
2013 Q4 | 2.67 Million INR | -46.38% |
2013 Q1 | 1.35 Million INR | -81.61% |
2013 Q3 | 4.99 Million INR | 321.98% |
2013 Q2 | 1.18 Million INR | -12.82% |
2012 Q1 | 1.21 Million INR | -6.04% |
2012 FY | - INR | 141.28% |
2012 Q2 | 1.05 Million INR | -13.64% |
2012 Q3 | 1.07 Million INR | 2.0% |
2012 Q4 | 7.37 Million INR | 588.41% |
2011 Q3 | 843 Thousand INR | 0.0% |
2011 Q4 | 1.29 Million INR | 53.65% |
2011 FY | - INR | -61.46% |
2010 FY | - INR | 78.55% |
2009 FY | - INR | 566.81% |
2008 FY | - INR | 48.72% |
2008 Q4 | -3.03 Million INR | 0.0% |
2007 FY | - INR | 0.0% |
2007 Q4 | -3.03 Million INR | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Aarey Drugs & Pharmaceuticals Limited | 45.16 Million INR | 71.226% |
Aarti Drugs Limited | 3.24 Billion INR | 99.6% |
Aarti Pharmalabs Limited | 3.9 Billion INR | 99.668% |
Ajanta Pharma Limited | 12.56 Billion INR | 99.897% |
Alembic Limited | 1.11 Billion INR | 98.836% |
Alkem Laboratories Limited | 24.19 Billion INR | 99.946% |
Alembic Pharmaceuticals Limited | 9.61 Billion INR | 99.865% |
AstraZeneca Pharma India Limited | 2.35 Billion INR | 99.449% |
Bal Pharma Limited | 345.59 Million INR | 96.239% |
Bliss GVS Pharma Limited | 1.47 Billion INR | 99.121% |
Brooks Laboratories Limited | 41.72 Million INR | 68.855% |
Bafna Pharmaceuticals Limited | 114.58 Million INR | 88.658% |
Caplin Point Laboratories Limited | 6.18 Billion INR | 99.79% |
Divi's Laboratories Limited | 25.43 Billion INR | 99.949% |
Eris Lifesciences Limited | 6.98 Billion INR | 99.814% |
Granules India Limited | 8.6 Billion INR | 99.849% |
Ind-Swift Limited | 1.06 Billion INR | 98.78% |
Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | 95.982% |
J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 99.861% |
Jubilant Pharmova Limited | 8 Billion INR | 99.838% |
Kilitch Drugs (India) Limited | 287.42 Million INR | 95.478% |
Medicamen Biotech Limited | 245.66 Million INR | 94.71% |
Medico Remedies Limited | 129.09 Million INR | 89.933% |
Wockhardt Limited | 1.08 Billion INR | 98.797% |
Orchid Pharma Limited | 1.41 Billion INR | 99.084% |
RPG Life Sciences Limited | 1.28 Billion INR | 98.986% |
Shilpa Medicare Limited | 2.58 Billion INR | 99.498% |
Sigachi Industries Limited | 883.39 Million INR | 98.529% |
Solara Active Pharma Sciences Limited | -2.82 Billion INR | 100.461% |
Unichem Laboratories Limited | 742.35 Million INR | 98.249% |
Vaishali Pharma Limited | 31.71 Million INR | 59.017% |
Wanbury Limited | 985.49 Million INR | 98.681% |
Zydus Lifesciences Limited | 56.22 Billion INR | 99.977% |
FDC Limited | 3.38 Billion INR | 99.616% |
Amrutanjan Health Care Limited | 681.59 Million INR | 98.093% |
Bajaj HealthCare Limited | 406.23 Million INR | 96.801% |
Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 99.985% |
Glenmark Life Sciences Limited | 6.86 Billion INR | 99.811% |
Ind-Swift Laboratories Limited | 6.86 Billion INR | 99.811% |
Laurus Labs Limited | 8 Billion INR | 99.838% |
Mangalam Drugs & Organics Limited | 174.94 Million INR | 92.571% |
Nectar Lifesciences Limited | 1.53 Billion INR | 99.154% |
Par Drugs and Chemicals Limited | 228.17 Million INR | 94.304% |
Hester Biosciences Limited | 539.47 Million INR | 97.591% |
Ipca Laboratories Limited | 13.29 Billion INR | 99.902% |
Venus Remedies Limited | 711.8 Million INR | 98.174% |
ZIM Laboratories Limited | 462.09 Million INR | 97.188% |
Aurobindo Pharma Limited | 61.78 Billion INR | 99.979% |
Morepen Laboratories Limited | 1.72 Billion INR | 99.247% |
Neuland Laboratories Limited | 4.74 Billion INR | 99.726% |
Sequent Scientific Limited | 549.8 Million INR | 97.636% |
Suven Pharmaceuticals Limited | 4.67 Billion INR | 99.722% |
Valiant Laboratories Limited | 12.73 Million INR | -2.017% |
Windlas Biotech Limited | 781.72 Million INR | 98.338% |
Hikal Limited | 2.69 Billion INR | 99.517% |
Innova Captab Limited | 1.66 Billion INR | 99.221% |
Procter & Gamble Health Limited | 3.07 Billion INR | 99.577% |
Themis Medicare Limited | 562.6 Million INR | 97.69% |
IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | 99.501% |
Mankind Pharma Limited | 28.09 Billion INR | 99.954% |
Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 99.885% |
Sakar Healthcare Limited | 393.26 Million INR | 96.695% |
Albert David Limited | 1.04 Billion INR | 98.757% |
Lupin Limited | 36.96 Billion INR | 99.965% |
Gufic Biosciences Limited | 1.48 Billion INR | 99.122% |
Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 99.991% |
Lincoln Pharmaceuticals Limited | 1.34 Billion INR | 99.033% |
Syncom Formulations (India) Limited | 430.27 Million INR | 96.98% |
Piramal Enterprises Limited | -3.86 Billion INR | 100.337% |
Torrent Pharmaceuticals Limited | 35 Billion INR | 99.963% |
NATCO Pharma Limited | 18.79 Billion INR | 99.931% |
Suven Life Sciences Limited | -992.78 Million INR | 101.309% |
Krebs Biochemicals & Industries Limited | -82.72 Million INR | 115.71% |
Strides Pharma Science Limited | 3.76 Billion INR | 99.655% |
Indoco Remedies Limited | 2.64 Billion INR | 99.509% |
Alpa Laboratories Limited | 229.96 Million INR | 94.349% |
Lasa Supergenerics Limited | -65.08 Million INR | 119.969% |
Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 100.348% |